Krill Oil Study Compared to Fish Oil

NCT ID: NCT01323036

Last Updated: 2012-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main purpose of the study is to evaluate the absorption of omega-3 fatty acids into the blood following consumption of krill oil compared with fish oil and placebo. An additional purpose is to evaluate the lipid-lowering efficacy and safety of consumption of Krill Oil and Fish Oil to a placebo product. It has been shown that the ingestion of Krill Oil leads to better absorption of omega-3 fatty acids compared to ingestion of Fish Oil. It was also shown that consumption of krill oil and fish oil result in a favorable modification of lipid profiles. Therefore, it is anticipated that consumption of these krill oil and fish oil will improve lipid profile, as well as other health-related markers and will be safe and well tolerated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Krill Oil

Group Type EXPERIMENTAL

Krill oil

Intervention Type DIETARY_SUPPLEMENT

Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg

Fish Oil

Group Type EXPERIMENTAL

Fish Oil

Intervention Type DIETARY_SUPPLEMENT

Fish oil: Total omega-3 fatty acids: 560-660 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Krill oil

Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg

Intervention Type DIETARY_SUPPLEMENT

Fish Oil

Fish oil: Total omega-3 fatty acids: 560-660 mg

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy men and premenopausal not pregnant or nursing women between 18 and 49 years old.

Exclusion Criteria

* smokers
* rheumatoid arthritis
* chronic illness
* cardiovascular problems
* dyslipidemia
* liver and kidney disease
* diabetes
* endocrine or metabolic disease
* inflammatory bowel disease
* pancreatitis
* gallbladder or biliary disease
* neurological/psychological disease
* bleeding disorders
* experienced platelet abnormalities
* gastrointestinal disorders that could interfere with fat absorption
* hypertension
* history of cancer
* an intention to lose weight
* use of anticoagulant
* serum triglycerides (TG) \>200 mg/dL, and/or total cholesterol (TC) \>240 mg/dL, and/or LDL-cholesterol (LDL-C) \>160 mg/dL
* hypertension or lipid lowering medications
* consumption of more than one alcoholic drinks/day
* Consumption of more than one fish or seafood serving
* one month prior to the start of the study
* omega-6 fatty acids in the past 6 months
* planned to consume seafood products or fish or to use any omega-3 or omega-6 fatty acids nutritional supplements at anytime in the duration of the study
* planned to to become pregnant during the study period
* BMI\>28
* allergies to fish seafood or corn
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Enzymotec

INDUSTRY

Sponsor Role collaborator

University of Manitoba

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr. Peter Jones

Director of RCFFN

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Richardson Centre for Functional Foods and Nutraceuticals

Winnipeg, Manitoba, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Ramprasath VR, Eyal I, Zchut S, Shafat I, Jones PJ. Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil. Lipids Health Dis. 2015 Nov 4;14:142. doi: 10.1186/s12944-015-0142-y.

Reference Type DERIVED
PMID: 26537218 (View on PubMed)

Ramprasath VR, Eyal I, Zchut S, Jones PJ. Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis. 2013 Dec 5;12:178. doi: 10.1186/1476-511X-12-178.

Reference Type DERIVED
PMID: 24304605 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B2011:014

Identifier Type: -

Identifier Source: org_study_id